Marc Kottmaier

Marc Kottmaier

Auto-generated profile, based on publicly available information

Marc Kottmaier

Department of Electrophysiology, German Heart Center Munich Technical University of Munich Munich Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2023 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Open access
MPMiruna A. Popa
Miruna A. Popa
FBFabian Bahlke
Fabian Bahlke
MKMarc Kottmaier
Marc Kottmaier
LFLeonie Foerschner
Leonie Foerschner
FBFelix Bourier
Felix Bourier
IDIsabel Deisenhofer
Isabel Deisenhofer
Introduction: Pulmonary vein isolation (PVI) using radiofrequency ablation (RFA) is an established treatment strategy for atrial fibrillation (AF). To improve PVI efficacy and safety, high‐power short‐duration (HPSD) ablation and pulsed‐field ablation (PFA) were recently introduced into clinical practice. This study aimed to determine the extent of myocardial injury and systemic inflammation following PFA, HPSD, and standard RFA using established biomarkers.Methods: We included 179 patients with paroxysmal AF receiving first‐time PVI with different ablation technologies: standard RFA (30–40 W/20–30 s, n = 52), power‐controlled HPSD (70 W/5–7 s, n = 60), temperature‐controlled HPSD (90 W/4 s, n = 32), and PFA (biphasic, bipolar waveform, n = 35). High‐sensitivity cardiac troponin T (hs‐cTnT), creatine kinase (CK), CK MB isoform (CK‐MB), and white blood cell (WBC) count were determined before and after ablation.Results: Baseline characteristics were well‐balanced between groups (age 63.1 ± 10.3 years, 61.5% male). Postablation hs‐cTnT release was significantly higher with PFA (1469.3 ± 495.0 ng/L), HPSD‐70W (1322.3 ± 510.6 ng/L), and HPSD‐90W (1441.2 ± 409.9 ng/L) than with standard RFA (1045.9 ± 369.7 ng/L; p < .001). CK and CK‐MB release was increased with PFA by 3.4‐fold and 5.8‐fold, respectively, as compared to standard RFA (p < .001). PFA was associated with the lowest elevation in WBC (Δ1.5 ± 1.5 × 109/L), as compared to standard RFA (Δ3.8 ± 2.5 × 109/L, p < .001), HPSD‐70W (Δ2.7 ± 1.7 × 109/L, p = .037), and HPSD‐90W (Δ3.6 ± 2.5 × 109/L, p < .001).Conclusion: Among the four investigated ablation technologies, PFA was associated with the highest myocardial injury and the lowest inflammatory reaction.

12 December 2022 in EP Europace
Verified
Journal Article
Open access
PDF file
MPMiruna A. Popa
Miruna A. Popa
FBFelix Bourier
Felix Bourier
SLSarah Lengauer
Sarah Lengauer
HKHannah Krafft
Hannah Krafft
FBFabian Bahlke
Fabian Bahlke
MKMarc Kottmaier
Marc Kottmaier
This retrospective study sought to compare complication rates and efficacy of power-controlled very high-power short-duration (vHPSD) and conventional catheter ablation in a large cohort of patients with atrial fibrillation (AF). We analyzed 1115 consecutive patients with AF (38.7% paroxysmal, 61.3% persistent) who received first-time catheter ablation at our centre from 2015 to 2021. Circumferential pulmonary vein isolation ± additional substrate ablation using an irrigated-tip catheter was performed with vHPSD (70 W/5–7 s or 60 W/7–10 s) in 574 patients and with conventional power (30–35 W/15–30 s) in 541 patients. Baseline characteristics were well-balanced between groups (mean age 65.1 ± 11.2 years, 63.4% male). The 30-day incidence of cardiac tamponade [2/574 (0.35%) vs. 1/541 (0.18%), P = 0.598], pericardial effusion ≥ 10 mm [2/574 (0.35%) vs. 1/541 (0.18%), P = 0.598] and transient ischaemic attack [1/574 (0.17%) vs. 2/541 (0.37%), P = 0.529] was not significantly different between vHPSD and conventional ablation. No stroke, atrio-esophageal fistula, cardiac arrest or death occurred. Procedure (122.2 ± 46.8 min vs. 155.0 ± 50.5 min, P < 0.001), radiofrequency (22.4 ± 19.3 min vs. 52.9 ± 22.0 min, P < 0.001), and fluoroscopy (8.1 ± 7.2 vs. 9.2 ± 7.4, P = 0.016) duration were significantly shorter in the vHPSD group. At 12 months follow-up, freedom of any atrial arrhythmia was 44.1% vs. 34.2% (P = 0.010) in persistent AF and 78.1% vs. 70.2% in paroxysmal AF (P = 0.068). vHPSD ablation is as safe as conventional ablation and is associated with an improved long-term efficacy in persistent AF.

29 April 2021 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
FBFelix Bourier
Felix Bourier
MPMiruna Popa
Miruna Popa
MKMarc Kottmaier
Marc Kottmaier
SMSusanne Maurer
Susanne Maurer
FBFabian Bahlke
Fabian Bahlke
IDIsabel Deisenhofer
Isabel Deisenhofer

10 January 2024 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Open access
FBFabian Bahlke
Fabian Bahlke
FEFlorian Englert
Florian Englert
MPMiruna A. Popa
Miruna A. Popa
FBFelix Bourier
Felix Bourier
TRTilko Reents
Tilko Reents
NENico Erhard
Nico Erhard
Introduction: Despite advanced ablation strategies and major technological improvements, treatment of persistent atrial fibrillation (AF) remains challenging and the underlying pathophysiology is not fully understood. This study analyzed the multiple procedure outcome and safety of catheter ablation of spatiotemporal dispersions (DISPERS) detected by artificial intelligence (AI)‐guided software in patients with long‐standing persistent AF.Methods and Results: The Volta VX1 software was used for 50 consecutive patients undergoing catheter ablation for persistent AF. First, high‐density mapping (78% biatrial) with a multipolar mapping catheter was performed. In addition to pulmonary vein isolation (PVI), ablation of DISPERS was performed aiming at homogenizing, dissecting, isolating, or connecting DISPERS areas to nonconducting anatomical structures. Follow‐up contained regular visits at our outpatient clinic at 1, 3, 6, and 12 months including 7‐day Holter electrocardiograms. Patients were mainly suffering from long‐standing persistent AF (mean AF duration 50.30 ± 54.28 months). Following PVI, ablation of left atrial and right atrial DISPERS areas led to AF cycle length prolongation (mean of 162.0 ± 16.6 to 202.2 ± 21.6 ms after) and AF termination to atrial tachycardia (AT) or sinus rhythm (SR) in 12 patients (24%). No stroke or pericardial effusion occurred; major groin complications (pseudoaneurysm n = 1, atrioventricular fistula n = 1) were detected in two patients. After a blanking period of 6 weeks, recurrence of any atrial arrhythmia was documented in 26 patients (52%). The majority of patients presented with organized AT (n = 15) while AF was present in n = 9 patients and AT/AF was observed in n = 2 patients. Twenty‐two patients underwent reablation. During a mean follow‐up of 363.14 ± 187.42 days and after an average of 1.46 ± 0.68 procedures, 82% of patients remained in stable SR.Conclusion: DISPERS‐guided ablation using machine learning software (the Volta VX1 software) in addition to PVI in long‐standing persistent AF ablation resulted in high long‐term success rates regarding AF and AT elimination. Most arrhythmia recurrences were reentrant AT. After a total of 1.46 ± 0.68 procedures, freedom from AF/AT was 82%. Despite prolonged procedure times complication rates were low. Randomized studies are necessary to evaluate long‐term efficacy of dispersion‐guided ablation using AI.

1 February 2018 in The American Journal of Cardiology
Verified
Journal Article
Closed access
MKMarc Kottmaier
Marc Kottmaier
FBFelix Bourier
Felix Bourier
HPHannah Pausch
Hannah Pausch
TRTilko Reents
Tilko Reents
VSVerena Semmler
Verena Semmler
IDIsabel Deisenhofer
Isabel Deisenhofer

26 July 2018 in Clinical Research in Cardiology
Verified
Journal Article
Closed access
PDF file
MKMarc Kottmaier
Marc Kottmaier
CJClemens Jilek
Clemens Jilek
SBSophie Berglar
Sophie Berglar
TRTilko Reents
Tilko Reents
FBFelix Bourier
Felix Bourier
IDIsabel Deisenhofer
Isabel Deisenhofer